Investor Presentaiton

Innovation and Globalization are Our Key Strategies . Expand in global markets FDA IND approvals for 7 pipelines 6 assets under global development • Development/registration collaborations with leading global pharmaceutical companies Accelerate the expansion of US and Europe subsidiary Accelerate global development of pipeline portfolio Anticipate BLA filing with the U.S. FDA for TYVYTⓇ in NSCLC in 2021: 2020.08: ex-China rights out licensed to Lilly; total deal value >US$1Bn Maximized potential for a global TYVYTⓇ collaboration with Lilly; develop global brand to support future commercial efforts of the Company 2021: Anticipate BLA acceptance by the U.S. FDA for TYVYTⓇ in NSCLC. IBI-305 (bevacizumab injection): PT Etana to file NDA in Indonesia in 2021; Out licensed north America rights to Coherus IBI-188 (CD47): Phase 1b ongoing in China and US IBI-322 (PD-L1/CD47): Phase 1 ongoing in both China and US IBI-939 (TIGIT): IND approved by US FDA, global development plan IBI-110 (LAG-3): IND approved by US FDA, global development plan THE UNIVERSITY OF TEXAS MD Anderson Coherus Cancer Center BIOSCIENCES Making Cancer History" Lilly etana Biotech Innovent Leverage the advantages of China clinical development to accelerate pipeline's global development and registration. Innovent Expand overseas talent team as to fit the increasing global operation needs. Confidential Copyright©2021 Innovent Biologics 34

View entire presentation